Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab

Novel predictive biomarkers are needed to improve patient selection and optimize the use of bevacizumab (B) in metastatic colorectal cancer. We analyzed the potential of five circulating biomarkers to predict B efficacy and monitor response. Peripheral blood samples collected at baseline, at the fir...

Descripción completa

Detalles Bibliográficos
Autores principales: Marisi, Giorgia, Scarpi, Emanuela, Passardi, Alessandro, Nanni, Oriana, Ragazzini, Angela, Valgiusti, Martina, Casadei Gardini, Andrea, Neri, Luca Maria, Frassineti, Giovanni Luca, Amadori, Dino, Ulivi, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431064/
https://www.ncbi.nlm.nih.gov/pubmed/28465540
http://dx.doi.org/10.1038/s41598-017-01420-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431064/
https://www.ncbi.nlm.nih.gov/pubmed/28465540
http://dx.doi.org/10.1038/s41598-017-01420-0

Ejemplares similares